Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

U.S. senator wants to know how the FDA will enforce drug ad regulations after letting go numerous workers from the office ...

Trump's tariffs continue to affect the global economy and markets. Follow for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Matt takes a moment to chat about some of the most popular theories in the Big Pharma Conspiracy umbrella.

Freedom of speech, assembly, and due process are being shredded in real time by the felon-in-chief as Republicans on Capitol ...

The NHS faces a crackdown on payments from pharmaceutical companies after The i Paper revealed that mental health medics have ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

Joining with Democratic U.S. Sen. Jeanne Shaheen of New Hampshire, Missouri’s senior GOP senator wants to end federal ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...